In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Gregory Yh Lip
Speaker
Gregory Yh Lip
Gregory Yh Lip Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)

Speciality : Atrial Fibrillation

115 presentations from this speaker

“CC to ABC”: AF characterization and holistic integrated care – From 5 Domains to ABC approach.

Event : ESC Congress 2020

  • Session : 2020 ESC Guidelines on Atrial Fibrillation
  • Speaker : GYH Lip (Liverpool,GB)

2020 ESC Guidelines on Atrial Fibrillation - Live.

Event : ESC Congress 2020

  • Session : 2020 ESC Guidelines on Atrial Fibrillation - Live
  • Speaker : G Hindricks (Leipzig,DE), IC Van Gelder (Groningen,NL), G Boriani (Castenaso-Bo,IT), GYH Lip (Liverpool,GB), C Blomstrom-Lundqvist (Uppsala,SE), E Arbelo (Barcelona,ES), TS Potpara (Belgrade,RS)

Advances in anticoagulation: balancing safety and efficacy.

Event : ESC Congress 2020

  • Session : Atrial fibrillation patients in focus: clinical cases and guidelines
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Atrial Fibrillation management: from clinical evidence to real world practice

Event : ESC Asia 2020

  • Session : Atrial Fibrillation (AF) Management: from clinical evidence to real world practice
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Case 1 - A patient with renal insufficiency - What is the optimal anticoagulation?

Event : ESC Congress 2020

  • Session : Meet the Experts - Challenging Decisions in Anticoagulation Therapy
  • Speaker : GYH Lip (Liverpool,GB)

How routine clinical practice data should supplement the results from clinical trials?

Event : ESC Congress 2020

  • Session : How evidence from routine clinical practice can improve the care of the elderly atrial fibrillation patient?
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

Q&A and conclusion - Atrial Fibrillation Management: from clinical evidence to real world practice

Event : ESC Asia 2020

  • Session : Atrial Fibrillation (AF) Management: from clinical evidence to real world practice
  • Speaker : MF Ramirez (Metro Manila,PH), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Summary and conclusions.

Event : EHRA Essentials 4 You 2020

  • Session : Recent developments in risk stratification and early AF detection for the improved prevention of stroke and systemic embolic events
  • Speaker : GYH Lip (Liverpool,GB)
  • Industry Essentials organised by Daiichi Sankyo Europe

Welcome, introduction and summary of hot topics discussed.

Event : EHRA Essentials 4 You 2020

  • Session : Recent developments in risk stratification and early AF detection for the improved prevention of stroke and systemic embolic events
  • Speaker : GYH Lip (Liverpool,GB)
  • Industry Essentials organised by Daiichi Sankyo Europe

Who is at risk to develop atrial fibrillation?

Event : EHRA Essentials 4 You 2020

  • Session : EHRA/HRS/APHRS/LAHRS Expert Consensus 2020: risk assessment in cardiac arrhythmias: use the right tool for the right outcome in the right population
  • Speaker : GYH Lip (Liverpool,GB)

Antithrombotic therapy in atrial fibrillation patients post-PCI: guidance from both sides of the Atlantic

Event : ESC Congress 2019

  • Session : Antithrombotic therapy in atrial fibrillation patients post-percutaneous coronary intervention: guidance from both sides of the Atlantic
  • Speaker : C Cannon (Boston,US), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Establishing NOACs as standard of care in clinical practice

Event : ESC Congress 2019

  • Session : Non-vitamin K antagonist oral anticoagulants (NOACs): from new evidence to improved patient outcomes in atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by The Bristol-Myers Squibb/Pfizer Alliance

NOAC safety profiles: assessing patient outcomes in the real world

Event : ESC Congress 2019

  • Session : 10 years since RE-LY: comprehensive experience for atrial fibrillation patients
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Quickfire questions and answers: anticoagulation in atrial fibrillation patients with cardiac comorbidities

Event : ESC Congress 2019

  • Session : 10 years since RE-LY: comprehensive experience for atrial fibrillation patients
  • Speaker : J Eikelboom (Hamilton,CA), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Quickfire questions and answers: anticoagulation in atrial fibrillation patients with comorbidities

Event : ESC Congress 2019

  • Session : 10 years since RE-LY: comprehensive experience for atrial fibrillation patients
  • Speaker : J Eikelboom (Hamilton,CA), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Quickfire questions and answers: NOAC safety profiles

Event : ESC Congress 2019

  • Session : 10 years since RE-LY: comprehensive experience for atrial fibrillation patients
  • Speaker : J Eikelboom (Hamilton,CA), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

State of the Art - Hot topics in stroke prevention in atrial fibrillation

Event : ESC Congress 2019

  • Session : Challenges in the management of atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)

Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

Event : ESC Congress 2019

  • Session : Atrial fibrillation and oral anticoagulation 5
  • Speaker : GYH Lip (Liverpool,GB)

Beyond trials: learning from clinical practice.

Event : ESC Congress 2018

  • Session : Advances in anticoagulation to improve patient care in atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Discussion and close: anticoagulation in atrial fibrillation and beyond.

Event : ESC Congress 2018

  • Session : Dabigatran use in diverse cardiology settings
  • Speaker : J Halperin (New York,US), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

GLORIA-AF: latest results from this prospective study.

Event : ESC Congress 2018

  • Session : Anticoagulation and your atrial fibrillation patients: bringing it all together in clinical practice
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Introduction: balancing thrombosis and bleeding in AF/ACS/PCI.

Event : ESC Congress 2018

  • Session : 2018 Joint European Consensus Document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions
  • Speaker : GYH Lip (Liverpool,GB)

Key messages of the 2018 consensus document on atrial fibrillation with acute coronary syndrome or stenting

Event : ESC Congress 2018

  • Session : Atrial fibrillation in the context of acute coronary syndromes and coronary intervention: what should we do?
  • Speaker : GYH Lip (Liverpool,GB)

Latest developments for dual vs triple antithrombotic therapy post-PCI.

Event : ESC Congress 2018

  • Session : Dabigatran use in diverse cardiology settings
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Moving beyond pharmacologic therapy in cardiac arrhythmia management

Event : ESC Congress 2018

  • Session : Navigating the continuum of care in cardiac arrhythmia management
  • Speaker : R De Caterina (Pisa,IT), GYH Lip (Liverpool,GB), G Hindricks (Leipzig,DE), M Duytschaever (Brugge,BE)
  • Organised by Medscape Education, supported with an educational grant by Biosense Webster

NOACs today: safety, efficacy, reversibility.

Event : EHRA 2018

  • Session : Uninterrupted dabigatran: exploring the impact on AF ablation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Panel discussion and conclusions - Anticoagulation and cancer: will recent evidence change clinical practice?

Event : ESC Congress 2018

  • Session : Anticoagulation and cancer: will recent evidence change clinical practice?
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmBH

Q&A: addressing AF ablation for your patients.

Event : EHRA 2018

  • Session : Uninterrupted dabigatran: exploring the impact on AF ablation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Questions & Answers - Leading the way in anticoagulation care in AF patients.

Event : EHRA 2018

  • Session : Leading the way in anticoagulation care in Atrial Fibrillation (AF) patients
  • Speaker : AJ Camm (London,GB), GYH Lip (Liverpool,GB), H Heidbuchel (Antwerp,BE), S Hohnloser (Koenigstein,DE)
  • Sponsored by BMS Pfizer

Role of duration of atrial fibrillation and risk of stroke

Event : EHRA 2018

  • Session : Blood pressure, atrial fibrillation and the brain
  • Speaker : GYH Lip (Liverpool,GB)

Safety of uninterrupted dabigatran in cardiovascular interventions in the GLORIA-AF registry program

Event : EHRA 2018

  • Session : What is new in atrial fibrillation?
  • Speaker : GYH Lip (Liverpool,GB)

Stroke prevention strategies in atrial fibrillation on both sides of the Atlantic

Event : ESC Congress 2018

  • Session : Atrial fibrillation in 2018
  • Speaker : GYH Lip (Liverpool,GB)
  • Joint with the American Heart Association

Translating New Oral Anticoagulant (NOAC) evidence into clinical practice: optimising patient outcomes.

Event : EHRA 2018

  • Session : Leading the way in anticoagulation care in Atrial Fibrillation (AF) patients
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by BMS Pfizer

Welcome and introduction - Interaction between cancer and coagulation.

Event : ESC Congress 2018

  • Session : Anticoagulation and cancer: will recent evidence change clinical practice?
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmBH

Anticoagulation care in the electrophysiology lab: what do we know so far?

Event : EHRA 2017

  • Session : RE-CIRCUIT: uninterrupted dabigatran as a new strategy in atrial fibrillation ablation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Atrial fibrillation: dilemmas in risk stratification and stroke prevention.

Event : ESC Congress 2017

  • Session : Atrial high rate episodes and subclinical atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)

Audience Q&A - Breakthroughs in AF: from RE-CIRCUIT to reversal.

Event : ESC Congress 2017

  • Session : Breakthroughs in AF: from RE-CIRCUIT to reversal
  • Speaker : GYH Lip (Liverpool,GB), H Calkins (Baltimore,US)
  • Sponsored by Boehringer Ingelheim

Audience Q&A.

Event : EHRA 2017

  • Session : RE-CIRCUIT: uninterrupted dabigatran as a new strategy in atrial fibrillation ablation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Choosing the right anticoagulant for the right patient.

Event : EHRA 2017

  • Session : State of the art on anticoagulation
  • Speaker : GYH Lip (Liverpool,GB)

EHRA/Council on Hypertension: consensus statement on atrial fibrillation in hypertension

Event : ESC Congress 2017

  • Session : Arrhythmias in hypertension
  • Speaker : GYH Lip (Liverpool,GB)

Living up to expectations: patient outcomes with NOACs in clinical practice.

Event : ESC Congress 2017

  • Session : Expanding our knowledge of NOACs in SPAF: from evidence to enhanced patient outcomes
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

OAC choice: what’s really important for physicians and patients.

Event : ESC Congress 2017

  • Session : Anticoagulation care: covering all the bases
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Overview of recent EHRA scientific documents.

Event : EHRA 2017

  • Session : Congress Highlights
  • Speaker : GYH Lip (Liverpool,GB)

Periprocedural oral anticoagulant use: an evolving field.

Event : ESC Congress 2017

  • Session : Breakthroughs in AF: from RE-CIRCUIT to reversal
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Stroke prevention in atrial fibrillation: discussing optimal care with NOACs for complex patients.

Event : ESC Congress 2017

  • Session : Stroke prevention in atrial fibrillation: discussing optimal care with NOACs for complex patients
  • Speaker : S Hohnloser (Koenigstein,DE), A Budaj (Warsaw,PL), GYH Lip (Liverpool,GB)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

What the consensus document says.

Event : EHRA 2017

  • Session : Antithrombotic therapy in valvular atrial fibrillation: joint position document from EHRA and WG thrombosis
  • Speaker : GYH Lip (Liverpool,GB)

ANNEXA-4 - Discussant review

Event : ESC Congress 2016

  • Session : Hot Line preventive strategies 2
  • Speaker : GYH Lip (Liverpool,GB)

Are all NOACs the same? Insights from clinical practice.

Event : ESC Congress 2016

  • Session : Are all NOACs the same? Insights from clinical practice
  • Speaker : GYH Lip (Liverpool,GB), L De Luca (Roma,IT), B Vrijens (Liege,BE)
  • Sponsored by Boehringer Ingelheim

Audience Q&A - The future is now: impact of oral anticoagulation reversal on your practice.

Event : ESC Congress 2016

  • Session : The future is now: impact of oral anticoagulation reversal on your practice
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Bleeding risk for non-valvular AF patients prescribed warfarin, or standard doses of apixaban 5mg BID, dabigatran 150mg BID or rivaroxaban 20mg QD in real-world practice: Findings from EHR

Event : ESC Congress 2016

  • Session : Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?
  • Speaker : GYH Lip (Liverpool,GB)

Can real world data in NVAF add to clinical practice decisions? Your questions answered.

Event : ESC Congress 2016

  • Session : Can real world data in NVAF add to clinical practice decisions? Your questions answered
  • Speaker : GYH Lip (Liverpool,GB), S Johnsen (Aalborg,DK)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Comparison of oral anti-coagulants for stroke prevention in non-valvular atrial fibrillation: a multi-criteria decision analysis

Event : ESC Congress 2016

  • Session : Best Posters in anticoagulants in day to day practice - Issues to bear in mind
  • Speaker : GYH Lip (Liverpool,GB)

ENSURE-AF: edoxaban in subjects undergoing cardioversion.

Event : ESC Congress 2016

  • Session : Non-vitamin K antagonist oral anticoagulants and cardioversion: the experts talk
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

Panel discussion - Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications.

Event : ESC Congress 2016

  • Session : Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications
  • Speaker : J Weitz (Hamilton,CA), GYH Lip (Liverpool,GB), R Giugliano (Boston,US), A Goette (Paderborn,DE), H Heidbuchel (Antwerp,BE)
  • Sponsored by Daiichi Sankyo Europe GmbH

State of the art in unresolved issues in chronic anticoagulation.

Event : ESC Congress 2016

  • Session : Anticoagulant strategies in cardio embolic disease
  • Speaker : GYH Lip (Liverpool,GB)

Stroke prevention

Event : ESC Congress 2016

  • Session : Atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)
  • Joint with the Lancet

Summary and key messages - Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications.

Event : ESC Congress 2016

  • Session : Expanding current insights of non-vitamin K antagonist oral anticoagulants in atrial fibrillation: clinical implications
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

Thrombosis versus bleeding risk in NVAF patients – From trials to clinical practice.

Event : ESC Congress 2016

  • Session : Oral anticoagulation, thrombosis and bleeding – Improving patient care with NOACs
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

When should I use reversal agents for NOACs?

Event : ESC Congress 2016

  • Session : Reversal of NOACs' effect: when and how?
  • Speaker : GYH Lip (Liverpool,GB)

AEGEAN: Discussant review.

Event : ESC Congress 2015

  • Session : Hot Line II - Atrial fibrillation/Pacing
  • Speaker : GYH Lip (Liverpool,GB)

An ederly hypertensive patient with AF: how best to assess and balance risk of hemorrhage and stroke? What do the Guidelines say?

Event : ESC Congress 2015

  • Session : Stroke and risk in atrial fibrillation: what do the Guidelines say?
  • Speaker : GYH Lip (Liverpool,GB)

Anticoagulation in atrial fibrillation - state of the art.

Event : EHRA 2015

  • Session : Atrial fibrillation and stroke in 2015
  • Speaker : GYH Lip (Liverpool,GB)

Anticoagulation with old and new drugs.

Event : EHRA 2015

  • Session : Differences in electrophysiology between Europe and Japan: do they really matter? An update of clinically relevant information
  • Speaker : GYH Lip (Liverpool,GB)

Anti-inflammatory agents.

Event : EHRA 2015

  • Session : Upstream treatment of atrial fibrillation: myth or reality?
  • Speaker : GYH Lip (Liverpool,GB)

Case 1: 82 year-old woman has HTN, Diabetic, cr 1.9 with paroxysmal atrial fibrillation; what would you recommend for anticoagulation?

Event : EHRA 2015

  • Session : Atrial fibrillation and heart failure: advances and gaps in knowledge in the elderly
  • Speaker : GYH Lip (Liverpool,GB)

Clinical challenges in oral anticoagulation: your questions discussed.

Event : ESC Congress 2015

  • Session : Clinical challenges in oral anticoagulation: your questions discussed
  • Speaker : GYH Lip (Liverpool,GB), H Darius (Berlin,DE), A Cohen (London,GB)
  • Sponsored by BMS-Pfizer Alliance

Exploring real-world evidence for oral anticoagulation.

Event : ESC Congress 2015

  • Session : Exploring the universe of oral anticoagulation in patients with non-valvular atrial fibrillation: continuing the journey
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by BMS-Pfizer Alliance

In whom, when and how re-install antithrombotic therapy in TIA/stroke.

Event : Acute Cardiovascular Care 2015

  • Session : Neurologic emergencies and acute cardiac care
  • Speaker : GYH Lip (Liverpool,GB)

Individualising OAC for stroke prevention in AF: What factors are important?

Event : EHRA 2015

  • Session : AF ablation management: Therapy, stroke prevention and monitoring
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Medtronic

Navigating the alphabet soup of acronyms: CHADS2, CHA2DS2-VASc, R2CHADS2, HAS-BLED, HEMORR2AGES, SAMe-TT2R2 .

Event : Acute Cardiovascular Care 2015

  • Session : Unmet needs in medical therapies for atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)

Non-vitamin K antagonist oral anticoagulants in patients on chronic anticoagulation – From evidence of clinical trials to daily practice.

Event : Acute Cardiovascular Care 2015

  • Session : Acute coronary care in patients on chronic anticoagulation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

Panel discussion and closing - Acute coronary care in patients on chronic anticoagulation.

Event : Acute Cardiovascular Care 2015

  • Session : Acute coronary care in patients on chronic anticoagulation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

Panel Discussion and closing remarks - Edoxaban – Engaging with the real world in atrial fibrillation.

Event : ESC Congress 2015

  • Session : Edoxaban – Engaging with the real world in atrial fibrillation
  • Speaker : C Bode (Freiburg,DE), R De Caterina (Pisa,IT), R Kreutz (Berlin,DE), C Ruff (Boston,US), J Steffel (Zurich,CH), GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

State of the Art in current status clinical use of anticoagulants.

Event : ESC Congress 2015

  • Session : Oral anticoagulants still in the focus
  • Speaker : GYH Lip (Liverpool,GB)

State-of-the-art: PCI in patients on NOACs.

Event : ESC Congress 2015

  • Session : State-of-the-art: Percutaneous Coronary Intervention (PCI) in patients on NOACs
  • Speaker : GYH Lip (Liverpool,GB), G Nickenig (Bonn,DE)
  • Sponsored by Boehringer Ingelheim

The journey continues: future perspectives on improving patient care.

Event : ESC Congress 2015

  • Session : Exploring the universe of oral anticoagulation in patients with non-valvular atrial fibrillation: continuing the journey
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by BMS-Pfizer Alliance

The wider world: stroke prevention in practice.

Event : ESC Congress 2015

  • Session : The new world of anticoagulation: NOACs in 2015 and beyond
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Thrombogenesis in atrial fibrillation – Virchows triad in 2015.

Event : EHRA 2015

  • Session : Atrial high rate episodes and stroke prevention – An update
  • Speaker : GYH Lip (Liverpool,GB)
  • Organised by AFNET, supported by an unrestricted educational grant from Daiichi Sankyo Europe

Use of oral anticoagulants in combination with antiplatelet therapy: insights from the GLORIA-AF registry

Event : ESC Congress 2015

  • Session : Platelets and antiplatelets therapy III
  • Speaker : GYH Lip (Liverpool,GB)

Ventricular Arrhythmias & Sudden Cardiac Death

Event : ESC Congress 2015

  • Session : ESC Clinical Practice Guidelines 2015 - Highlights
  • Speaker : GYH Lip (Liverpool,GB)

What have we learned and how can we advance antithrombotic treatment further?

Event : ESC Congress 2015

  • Session : Exploring the universe of oral anticoagulation in patients with non-valvular atrial fibrillation: continuing the journey
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by BMS-Pfizer Alliance

Which non-vitamin K antagonist oral anticoagulant for which patient - Treatment algorithms for anticoagulation in atrial fibrillation.

Event : ESC Congress 2015

  • Session : Edoxaban – Engaging with the real world in atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

Balancing the risk of stroke and bleeding in the treatment of patients with atrial fibrillation.

Event : ESC Congress 2014

  • Session : Meeting the challenges in atrial fibrillation management: the role of new oral anticoagulants
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation

Event : ESC Congress 2014

  • Session : Anticoagulants and stroke in atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)

Efficacy and safety of apixaban vs edoxaban for stroke prevention in non-valvular atrial fibrillation: an indirect treatment analysis

Event : ESC Congress 2014

  • Session : Novel anticoagulants: trials, cost, real life use
  • Speaker : GYH Lip (Liverpool,GB)

One-Year Follow-Up of the EURObservational Research Programme - Atrial Fibrillation General Registry Pilot Phase

Event : ESC Congress 2014

  • Session : Registry Hot Line: Atrial fibrillation and myocardial infarction
  • Speaker : GYH Lip (Liverpool,GB)

Panel discussion - Meeting the challenges in atrial fibrillation management.

Event : ESC Congress 2014

  • Session : Meeting the challenges in atrial fibrillation management: the role of new oral anticoagulants
  • Speaker : C Bode (Freiburg,DE), R De Caterina (Pisa,IT), R Giugliano (Boston,US), GYH Lip (Liverpool,GB), F Verheugt (Amsterdam,NL)
  • Sponsored by Daiichi Sankyo Europe GmbH

Protection from stroke for patients with newly diagnosed nonvalvular atrial fibrillation: Dorothy’s story.

Event : ESC Congress 2014

  • Session : Practical patient protection: celebrating the benefits of dabigatran 5 years on from RE-LY®
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

AF GEN Pilot: Eurobservational Research Program: Atrial Fibrillation General Registry Pilot Phase.

Event : ESC Congress 2013

  • Session : Registry Hot Line: Registries on prevention and treatment
  • Speaker : GYH Lip (Liverpool,GB)

AMADEUS: Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation

Event : ESC Congress 2013

  • Session : Clinical Trial Update Hot Line III: Updates on risk and outcome
  • Speaker : GYH Lip (Liverpool,GB)

Anticoagulant profiles — What you need to know.

Event : ESC Congress 2013

  • Session : New insights into the definitive management of venous thromboembolism
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by theheart.org / Medscape Education

Appropriate use of thromboembolic and bleeding risk scores.

Event : ESC Congress 2013

  • Session : Controversies in atrial fibrillation
  • Speaker : GYH Lip (Liverpool,GB)

Atrial fibrillation.

Event : ESC Congress 2013

  • Session : Hypertension and the heart
  • Speaker : GYH Lip (Liverpool,GB)

Combination therapy.

Event : ESC Congress 2013

  • Session : Antithrombotics in heart failure
  • Speaker : GYH Lip (Liverpool,GB)

Questions and answers and close: practical guidance for stroke prevention in atrial fibrillation.

Event : ESC Congress 2013

  • Session : Practical guidance for stroke prevention in atrial fibrillation - Interactive case studies
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Stroke prevention in atrial fibrillation: from guidelines to ‘real-world’ practice.

Event : ESC Congress 2013

  • Session : Practical guidance for stroke prevention in atrial fibrillation - Interactive case studies
  • Speaker : GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are